AstraZeneca is involved in the Compliance Investigation of foreign drugs or the current price reduction trend

Chinese police visited the Shanghai Office of AstraZeneca, a British pharmaceutical company, to become the third foreign company under investigation in China after GlaxoSmithKline and youshibi, foreign media reported yesterday GlaxoSmithKline has deliberately responded to the investigation by reducing the price of the drug AstraZeneca was investigated by police A spokesman for AstraZeneca said on Monday that Chinese police entered its Shanghai Office on Friday and took an employee for questioning Yesterday, AstraZeneca also confirmed that a sales representative was taken away by Shanghai police on Friday, but the company insisted that it was because of the personal reasons of the sales representative that the public security did not carry out other inspections on the company It's worth noting that recently, media reported that a netizen published a post about "exposing the embezzlement and bribery of tens of millions of yuan by Tao Mingzhe, director of anesthesia department of Shenzhen People's Hospital", reporting that Tao Mingzhe, deputy director of anesthesia department of Shenzhen People's Hospital, received high kickbacks from Druggists and equipment suppliers and consumables suppliers in the name of employees of anesthesia department of Shenzhen People's hospital Companies such as AstraZeneca, fresenyuskabi and Xinchen pharmaceutical were targeted for bribery The report posted on the Internet has aroused strong repercussions, and Shenzhen Municipal Commission for Discipline Inspection and health and Family Planning Commission have been involved in the investigation In response to this, the head of AstraZeneca's Public Relations Department replied to the media: "at present, the company has started the internal investigation process for the behavior of the sales team in Shenzhen, but due to the number of audit links, the investigation cycle is not clear." The price of foreign drugs may fall in response to the demand The Chinese government's crackdown on commercial bribery in the pharmaceutical industry has been expanding Therefore, the police's visit to AstraZeneca is also interpreted by the industry as another object of investigation for the increasingly tough attitude of the Chinese government towards the illegal behaviors of multinational companies in China Before that, GSK and youshibi, a Belgian multinational pharmaceutical company, had been investigated by relevant departments Recently, the head of the relevant department of the Ministry of public security met with Abbas Hussain, President of GlaxoSmithKline in charge of international affairs and a delegation in Beijing Abbas Hussain once again apologized on behalf of GSK's head office after GSK was accused of promoting the sale of drugs through bribery, thereby increasing the price of drugs Later, GlaxoSmithKline said in a statement that it plans to reduce the operating cost of drug prices by adjusting the operation mode, so as to enable more Chinese patients to obtain high-quality drugs Some insiders have analyzed that, with the expansion of the investigation on commercial bribery in the pharmaceutical industry, foreign drugs that have been enjoying the price preferential policies such as independent pricing, high quality and good price are likely to usher in a wave of price reduction.